Idelalisib promotes Bim-dependent apoptosis through AKT/FoxO3a in hepatocellular carcinoma

Idelalisib, a selective PI3Kδ inhibitor, has been approved by the FDA for chronic lymphocytic leukemia/small lymphocytic lymphoma treatment and for follicular lymphoma treatment when combined with rituximab. However, the mechanisms of effective action of idelalisib in hepatocellular carcinoma (HCC)...

Descripción completa

Detalles Bibliográficos
Autores principales: Yue, Dan, Sun, Xun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6141589/
https://www.ncbi.nlm.nih.gov/pubmed/30224718
http://dx.doi.org/10.1038/s41419-018-0960-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6141589/
https://www.ncbi.nlm.nih.gov/pubmed/30224718
http://dx.doi.org/10.1038/s41419-018-0960-8

Ejemplares similares